Hester Biosciences Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Hester Biosciences Ltd trades at ₹2,265, in a confirmed uptrend and 15 weeks into that stage. That is +13.5% against its own 200-day average. It sits at 82% of a 52-week range of ₹1,317 to ₹2,478. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 26 straight weeks.

Today the stock is in a confirmed uptrend — week 15 of stage 2, confirmed. At ₹2,265 it trades +13.5% versus its 200-day average and sits at 82% of its 52-week range (₹1,317–₹2,478).

Against the market, two honest reads. Cumulative: over the last 10.5 years the stock moved +415% while the NIFTY 500 moved +267% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 26 straight weeks — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

Story check

Hester Biosciences Ltd's story is not scored yet against the markers our research file set on 22 August 2026. Where it sits in its own cycle: Not stated in the research file. Our fortnightly research layers last read it on 22 August 2026.

What is proven. See the research file

What is not proven yet. If animal healthcare quarterly revenue falls below 20 Cr for two consecutive quarters after Q2 FY27 — meaning the third 'next quarter' promise also fails — the tender normalization thesis is broken, not delayed. That combined with any decline in poultry OPM below 24% would indicate the current earnings level is a local peak, not a genuine recovery, and the position should be exited.

🚨 What would change our mind. If animal healthcare quarterly revenue falls below 20 Cr for two consecutive quarters after Q2 FY27 — meaning the third 'next quarter' promise also fails — the tender normalization thesis is broken, not delayed. That combined with any decline in poultry OPM below 24% would indicate the current earnings level is a local peak, not a genuine recovery, and the position should be exited.

🚨 Layer 1 read, 22 August 2026 — DROP. The Rs 97 Cr profit is a written-off loan, not earnings — sales fell 8% and the tender failed a third time. Hester reported profit of Rs 97 Cr on sales of Rs 77 Cr in the June quarter. Profit cannot exceed sales from trading: Rs 89 Cr of it was the Gates Foundation cutting the loan to Hester's Africa arm from USD 12 million to USD 5 million and waiving the interest, plus a Rs 24 Cr one-off tax benefit. Real operating profit was about Rs 16-17 Cr, the same as the previous quarter, and sales were 8% LOWER than a year ago. There is a genuine good half — the poultry vaccine business grew 48% and its gross margin went from 69% to 78% — but the government-tender half, roughly a third of the business, has now failed to arrive for the third quarter running, with a fourth promise made. Every screen that…

What would change Layer 1’s mind. The timeline says animal-healthcare revenue below Rs 20 Cr for two consecutive quarters after Q2 FY27, together with poultry operating margin below 24%, means the thesis is broken rather than delayed. I sharpen it to the single observation that decides this ranking. The Q2 FY27 (September 2026) result is the fourth promised tender date: if consolidated revenue does not clear Rs 100 Cr in that quarter — the level Mar 2026 already reached — then the tender half has failed a fourth time, the flat…

The test written in advance. Management Credibility — Five Documented Reversals — Management Credibility — Five Documented Reversals by the next result.

The test written in advance. Government Tender Calendar — Structural vs Cyclical Question — Government Tender Calendar — Structural vs Cyclical Question by the next result.

What the company does. Hester's standalone business is genuinely improving — poultry grew 48%, standalone EBITDA rose 95%, and H9N2 is clearly adding volume. But the consolidated Jun 2026 net profit of 97 Cr is almost entirely an exceptional accounting gain from the Gates Foundation restructuring Hester Africa's loan, not operating earnings. The critical concern is that animal healthcare tender recovery has now been missed for the third time in two years, with management repeating the same 'next quarter' promise without explaining why the previous commitment failed.

🚨 What the surface reading misses. The surface reading is: PE at 30th percentile — below median, still some discount to history The research reads it further: PE has moved from the 7th percentile (three months ago at 31x) to the 30th percentile (now at 38x) as the stock re-rated 21%. The underlying earnings base has not changed — FY26 PAT 57 Cr and EPS 65.41 are still the clean reference. The TTM shows EPS 160 which is exceptional-inflated. The PE compression since the Sep 2024 peak is earnings-driven: FY24 PAT 21 Cr rose to FY26 PAT 57 Cr. The stock is no longer deeply cheap; it is moderately below its historical median.

🚨 What the surface reading misses. The surface reading is: 97% PAT growth signals strong acceleration The research reads it further: PAT growth has partial base-effect inflation: FY25 base was depressed by a 59% effective tax rate in Mar 2025 quarter. Stripping the base effect, underlying growth is approximately 30-40% — still genuine but less dramatic than headline. FY25 clean PAT approximately 35 Cr; FY26 PAT 57 Cr = approximately 63% real growth. The operating improvement is independently confirmed by OPM recovery from 18% (FY24) to 26% (FY26).

Lever 6 · Order-book wins — BUILDING. Government PPR and goatpox programs have now been deferred three times; Q2 FY27 is the fourth promised recovery date. What proves it keeps working: Animal Healthcare Tender Normalization. It stops working if Government immunization program budgets are cut, or the PPR program is redesigned to use cheaper imported vaccines rather than Hester's domestically manufactured ones — which would remove the volume driver without a commercial market alternative.

Lever 1 · Operating leverage — BUILDING. Facility capitalized, now at 60-65% utilization; incremental volume from H9N2 and export scale-up flows at high incremental margins. What proves it keeps working: Fill-Finish Facility Operating Leverage. It stops working if New regulatory requirements force costly facility modifications that negate the operating leverage benefit, or the BSL3 veterinary manufacturing license (still unpublished since the Nov 2025 guidance) is denied.

Sources: our stock research file (22 August 2026) · quarterly results through Jun 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Hester Biosciences Ltd reported ₹77.0 Cr of revenue in the Jun 26 quarter, −8.3% year on year. Over 10 years it has compounded at 12.7% a year. The last full year, FY26, came in at ₹333 Cr. The last four reported quarters add to ₹325 Cr.

FY26 revenue came in at ₹333 Cr (+7.1% on the year), capping 10 years at 12.7% compound. The latest quarter (Jun 26) printed ₹77.0 Cr, −8.3% year on year.

Pace check: the last four quarters averaged +5.1% growth against the decade's 12.7% — the current year is running slower than its own long-run rate.

Acceleration check: trailing-twelve-month revenue grew +3.8% over the last 4 quarters against +4.4%/yr over the last 8 — stabilising; TTM profit +260.5% vs +155.4%/yr — accelerating.

FY26-Q4. revenue ₹100 Cr and profit ₹17 Cr as reported.

FY27-Q1. revenue ₹77 Cr and profit ₹97 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Hester Biosciences Ltd's operating margin is 29.0% in the Jun 26 quarter, +2.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 18.0% to 38.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 29.0%, +2.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 18.0%–38.0%.

Why the margin moved: operating margin went +2.4 pp year on year while gross margin went +4.6 pp — the gain came mostly from the gross line: input costs and pricing.

FY26-Q4. revenue ₹100 Cr and profit ₹17 Cr as reported.

FY27-Q1. revenue ₹77 Cr and profit ₹97 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Hester Biosciences Ltd earned ₹97.0 Cr of net profit in the Jun 26 quarter. That quarter carries a one-off item larger than its own revenue, so the year-on-year figure is an artefact rather than a trading result. Full-year FY26 profit was ₹57.0 Cr. The 10-year compound rate is 11.6%. That is 126.0% of the quarter's revenue.

Jun 26 profit was ₹97.0 Cr, +470.6% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹57.0 Cr (+96.6%), and the 10-year compound rate is 11.6%.

🚨 Read this profit with care: at ₹97.0 Cr it is larger than the whole quarter's revenue of ₹77.0 Cr — no operating business earns more than it sells, so this is a one-off item (a debt-to-equity conversion, a tax write-back or an asset sale), not money the business earned. The underlying operations are running at 29.0% operating margin; the year-on-year jump and any P/E built on this number are artefacts of the one-off, not a real earnings turn.

FY26-Q4. revenue ₹100 Cr and profit ₹17 Cr as reported.

FY27-Q1. revenue ₹77 Cr and profit ₹97 Cr as reported.

Why-sources: our stock research file (22 August 2026) and the company’s own results for those quarters.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 3 fiscal years 165% of Hester Biosciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹64.0 Cr of operating cash against ₹57.0 Cr of profit. After ₹23.0 Cr of capital spending, ₹41.0 Cr was left as free cash.

FY26: operating cash of ₹64.0 Cr against reported profit of ₹57.0 Cr, leaving free cash of ₹41.0 Cr after ₹23.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 165% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

Why conversion sits at 165%: the cash cycle tightened 14 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Hester Biosciences Ltd's cash conversion cycle runs 318 days in FY26, down from 332 days in FY21. Capital spending ran ₹65.0 Cr over the last 3 years. At FY26 sales of ₹333 Cr each day of that cycle holds about ₹0.9 Cr, so roughly ₹290 Cr sits inside the business at any moment.

Why this happened. Hester Africa has multi-vaccine technology capability from the Tanzania plant and participates in the GALVmed-led VITAL program. Africa generated a large exceptional accounting gain in Q1 FY27 through the Gates Foundation loan amendment — principal reduced from USD 12 million to USD 5 million and interest waived. But the FY28 breakeven commitment confirmed in Nov 2025 was dropped without explanation by May 2026, and management currently describes Africa as a 'formative period' with quarter-to-quarter progress expected. The tax-free status runs through 2030. This remains a long-duration option, not a near-term driver.

FY26: debtors at 105 days, inventory at 323 days — roughly 10.6 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 318 days, tighter than FY21's 332.

The full loop: cash goes out to suppliers and production on day 0; stock waits 323 days to sell; customers pay about 105 days after that; and suppliers themselves are paid at 110 days — netting out to the 318-day cycle.

In money terms: at FY26 sales of ₹333 Cr, each day of the cycle holds about ₹0.9 Cr — so the 318-day loop keeps roughly ₹290 Cr sitting inside the business at any moment.

On the investment side: capital spending of ₹65.0 Cr over the last 3 fiscal years against ₹53.0 Cr of depreciation — building somewhat ahead of wear-and-tear. Capital work-in-progress stands at ₹9.0 Cr (FY26) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified

Hester Biosciences Ltd earns a ROCE of 15% in FY26. That is up from a trough of 9% in FY23. Return on invested capital clears the cost of that capital by −1.6 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 17.1% net margin on 0.49× asset turns.

FY26 ROCE is 15%, recovered from a FY23 trough of 9% — the full ladder below shows the fall and the climb, undoctored.

🚨 Why the return is what it is — the wiring (FY26): 17.1% net margin × 0.49× asset turns × 1.88× balance-sheet leverage ≈ 15.8% on equity. Margin is doing the heavy lifting; leverage is a meaningful part of the equation.

The capstone test — ROIC − WACC: 10.4% − 12.0% = a −1.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.

Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified

Hester Biosciences Ltd carries total debt of ₹195 Cr against shareholder equity of ₹368 Cr as of Mar 26, a debt-to-equity of 0.53. On the annual view that ratio went from 0.85 in FY22 to 0.53 in FY26. Read the returns elsewhere on this page with that leverage in mind.

Why this happened. The 182 Cr capex cycle completed by March 2026. Fill-finish now operates at 60-65% whole-plant utilization including BSL3 capacity. Depreciation stepped up (7 Cr in Jun 2026 vs 4 Cr prior). The facility is fungible between poultry and large-animal vaccines. Any incremental volume — whether from H9N2 domestic expansion or future export approvals — flows at 60-70% incremental margin because fixed costs are already absorbed in the current utilization base.

Mar 26: total debt of ₹195 Cr against shareholder equity of ₹368 Cr — a debt-to-equity of 0.53. On the annual view, debt-to-equity went from 0.85 (FY22) to 0.53 (FY26). Read the returns on this page with that leverage in mind.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Hester Biosciences Ltd moved a full percentage point over the last two years — the register is quiet. Promoters moved +0.0 points over the same window, to 53.7%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Foreign institutions: −0.2 points over 8 quarters to 0.3%; Promoters: +0.0 points over 8 quarters to 53.7%; Domestic institutions: +0.0 points over 8 quarters to 0.0%.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Hester Biosciences Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Hester Biosciences Ltd trades at 36.3× P/E, near the bottom of its own range — cheaper only 24% of the time. Its long-run median P/E is 47.0×, measured across 10.6 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 36.3× is near the bottom of its own range — cheaper only 24% of the time, against a long-run median of 47.0× measured over 10.6 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Why the multiple sits where it does: over the past year annual EPS moved +102.4% against a +8.7% price move — earnings outran the price, pushing the multiple DOWN its own range.

The price move, decomposed: over 5y, of the −2.3%/yr price move, ~+4.2%/yr came from earnings growth and ~−6.5 pp from the multiple (compressing); over 10y, of the +11.4%/yr price move, ~+10.6%/yr came from earnings growth and ~+0.8 pp from the multiple (roughly flat). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.

Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.

A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.

What the price assumes This reading works the multiple backwards. It asks one question: what yearly rate of profit growth is a buyer at the market price already paying for? The number is the growth rate that makes eleven years of profit — six years growing, then five fading — add up to that day's market price, once each year is discounted at 11% a year.

Solved at its 24 August 2026 price, Hester Biosciences Ltd was paying for profit growth of about 25.4% a year. Profit itself has compounded 11.6% a year over the past 10 years. Today the market pays 36.3× P/E, the 24th percentile of its own 11-year range.

What the two numbers say together. The multiple is low against its own past, and the growth the price is paying for is far above what this company has actually delivered. A multiple that looks low because earnings fell is not the same thing as a low bar to clear.

How to hold this number: it is a reading of one day's price, taken on 24 August 2026, not a running figure — every other number on this page, the multiple included, is read off the live quote as of 11 September 2026. A higher price is paying for more growth and a lower price for less, so it moves whenever the price does, and this page does not restate it between measurements.

Stage: Improving Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Hester Biosciences Ltd reads as improving on its fundamental arc. Improving — EPS growth bottomed 7 quarters ago at −8.6% and has held its recovery at +262.2%, ROCE lifting at 15.0%. The read is built from 8 quarters across 4 curves, on partial evidence.

Why it matters: a sustained climb off the trough is the setup this page is built to catch — the question moves to what you pay for it.

The latest quarter’s profit carries a one-off item larger than the operating base, so the profit curve is shown but does not vote in the stage call.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.

4-Factor Sector Score

61.0/100 — rank 2 of 3 in Pharma - Animal · 78% evidence confidence

Hester Biosciences Ltd scores 61.0 out of 100 against the 3 companies it is compared with in Pharma - Animal, ranking 2. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.

The four contributions add to the total exactly: 27.4 + 14.1 + 11.5 + 8 = 61. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Said versus delivered

What Hester Biosciences Ltd's management promised, set against what actually arrived — 4 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.

🚨 Animal Healthcare Recovery Delayed Again · 30 July 2026. In Jan 2026, management expected the delayed PPR and Goat Pox programs to commence in February and drive improved Q4 momentum. In May 2026, it said Q4 execution had started to pick up and that Animal Health would recover from that quarter onward. In Jul 2026, however, management said tender sales had again been delayed and moved to the next quarter, with no explanation for why the prior recovery expectation failed.

🚨 H9N2 Export Commercial Launch - Shifted from Imminent to Indefinitely Contingent Without Explanation · 15 May 2026. In the Nov 2025 call, management described H9N2 export sales as imminent following receipt of the manufacturing license anticipated by December, citing a clear regulatory pathway already established in India as the foundation for near-term export commencement. In the May 2026 call, with both marketing and manufacturing licenses now confirmed received, the export narrative has been materially downgraded with no timeline given and the opportunity framed as entirely dependent on each country's independent disease management approach and regulatory processes, with no acknowledgment of or explanation for the departure from the prior near-term commercial launch expectation.

Africa Operations FY28 Breakeven Target - Explicitly Confirmed On Track Then Silently Dropped · 15 May 2026. In the Nov 2025 call, management explicitly confirmed Africa operations were on track for its FY28 breakeven target, referencing it as a previously established commitment at a time when Africa was generating meaningful half-year profits. By the Jan 2026 call, Africa Q3 was flagged as impacted by timing delays and higher operating costs without any reconfirmation of the FY28 target. In the May 2026 call, Africa is discussed only in general strategic terms with no reference to the FY28 breakeven commitment, and when an analyst explicitly asked about subsidiary breakeven timelines in the Q&A, management responded only on India animal healthcare without addressing the Africa financial milestone.

Nepal Operations Outlook Reversal · 30 January 2026. Management shifted from a confident outlook anticipating a resumption of orders in H2 to a warning about the unit's sustainability. In November, they explicitly guided for institutional execution to resume in the second half, but by January, the narrative changed to evaluating strategic measures to ensure the unit's survival. Earlier call (Nov 2025): “However, we continue to maintain a strong market presence and expect institutional execution to resume by the second half of this year.” Later call (Jan 2026): “Our Nepal operations are going through a challenging phase, and we are carefully evaluating strategic measures to ensure sustainability.”

Every quote above is taken word for word from the company’s own earnings calls.

Frequently asked questions